ADTX$0.0003
Aditxt, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: OTC
Mkt Cap:$299.4K
Float & O/S:
Inst Own:
DilutionScan read 67 of Aditxt, Inc.'s SEC filings and found 7 warrant series, 7 convertibles, 1 ATM program, 1 equity line, 3 shelf registrations, 1 S-1 registration and 6 completed offerings on file for ADTX. The latest dilution event on file is an offering on Jul 16, 2026. Analysis updated Oct 15, 2026.
Signal8 Summary
ADTX
Delisting confirmed and going-concern warning
Snapshot
Aditxt is a biotech in extreme distress. FY 2025 revenue was just $3,000 while the company lost $41.7 million, and it has already overrun its cash runway with only $3.2 million remaining.
What's Happening Right Now
- : The Nasdaq Hearings Panel denied Aditxt's request to maintain its listing, confirming that trading will be suspended effective June 25, 2026.
- : Aditxt issued senior secured convertible notes with a 35% original issue discount to consolidate and refinance existing debt.
- : Founding CEO Amro Albanna, COO Rowena Albanna, and two board members resigned in a sweeping leadership overhaul.
